Second Quarter 2025 Financial and Business Update August 7, 2025 Forward-Looking Statements & Legal Disclaimers Jim Corbett Chief Executive Officer 3 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward-looking statem ...

Core Insights - AVITA Medical's RECELL technology demonstrates significant clinical benefits, including reduced hospital stays for burn patients, as highlighted in a recent study presented at the British Burn Association Annual Meeting [1][3] - The RECELL system utilizes a small sample of a patient's skin to create Spray-On Skin™ Cells, which leads to faster healing and less pain compared to traditional skin grafting methods [2][5] - The analysis of over 6,300 patients indicates a reduction in hospital stay by an average of 6.2 days or 35.7% when treated with RECELL compared to split-thickness autografts, resulting in approximately $300 million in cost savings over five years [8] Company Overview - AVITA Medical is a leader in therapeutic acute wound care, focusing on innovative solutions that enhance wound healing and accelerate patient recovery [5] - The RECELL System is FDA-approved for treating thermal burn wounds and full-thickness skin defects, and it is used in over 130 burn centers across the United States [4][5] - The company also holds exclusive rights to manufacture and distribute other wound care products, including PermeaDerm and Cohealyx™ [5] Market Impact - The RECELL technology is gaining traction in international markets, with approvals in Australia, Europe, and Japan for various skin healing applications [6] - The findings from the national registry analysis provide a clearer understanding of how RECELL influences clinical decisions and patient outcomes, reinforcing its economic value in healthcare [3][8]

Core Insights - AVITA Medical's RECELL technology has been awarded "Best New Technology Solution – Surgical" at the 2025 MedTech Breakthrough Awards, highlighting its innovative approach in acute wound care [1][4] - RECELL has treated over 30,000 patients globally and is FDA-approved for thermal burn wounds and full-thickness skin defects, demonstrating significant clinical benefits such as reduced donor skin requirements and faster recovery times [2][6] - The introduction of RECELL GO enhances procedural consistency and surgical team coordination, making it suitable for high-volume burn and trauma centers [3] Company Overview - AVITA Medical specializes in therapeutic acute wound care, focusing on technologies that optimize wound healing and accelerate patient recovery [6] - The RECELL System utilizes a patient's own skin to create Spray-On Skin Cells, providing an innovative solution for improved clinical outcomes [6][7] - In addition to RECELL, AVITA holds exclusive rights to manufacture and distribute PermeaDerm and Cohealyx in the U.S., expanding its product portfolio in wound care [6] Awards and Recognition - Dr. Katie Bush, Senior Vice President of Scientific & Medical Affairs at AVITA Medical, received the 2025 Emerald Pinnacle Healthcare Award, recognizing exceptional innovation and leadership in the medical device sector [5]

Market Opportunity - The company is positioned for leadership in a U S market exceeding $3 5 billion[7] - The Total Addressable Market (TAM) is scaling through portfolio expansion and efficient execution[7] - The company's TAM in the burn market alone is expanding from $450 million to $1 5 billion[9] Revenue Growth - The company has demonstrated sustained revenue growth with a strong Compound Annual Growth Rate (CAGR)[11] - In 2024, the company's commercial revenue reached $64 million[12] - The company estimates a CAGR of +47% through December 30, 2025, based on the midpoint of commercial revenue guidance for FY2025[12, 13] - The company's revenue has grown significantly from $10 million in 2019 to $64 million in 2024[12] Product Portfolio - The company's multi-product strategy enables case-level revenue growth[7] - The company's acute wound portfolio includes RECELL, Cohealyx, and PermeaDerm[9] - Potential revenue per case for a two-stage procedure (10% to 20% TBSA wound) could range from approximately $28,500 to $57,000[9]